Zongertinib

Brand names: Hernexeos · Active ingredient: Zongertinib

In short: HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test . This indication is approved under accelerated

Forms & strengths60 mg tablets: yellow, oval, biconvex, film-coated tablets, debossed with "L6" on one side and the Boehringer Ingelheim company symbol on the other side. Each tablet contains 60 mg of zongertinib.
LabelBoehringer Ingelheim Pharmaceuticals, Inc.
Label updatedAug 17, 2026

What is Zongertinib used for?

HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test .

This indication is approved under accelerated approval based on objective response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Zongertinib dosage

Select patients for treatment of unresectable or metastatic NSCLC based on the presence of HER2 (ERBB2) tyrosine kinase domain activating mutations in tumor or plasma specimens . If no mutation is detected in a plasma specimen, test tumor tissue. Information on FDA-authorized tests for HER2 (ERBB2) tyrosine kinase domain activating mutations is available at: http://www.fda.gov/CompanionDiagnostics.

The recommended dosage of HERNEXEOS is based on body weight:

Patients weighing less than 90 kg: 120 mg

Patients weighing 90 kg or greater: 180 mg

Take HERNEXEOS orally once daily with or without food until disease progression or unacceptable toxicity. Swallow HERNEXEOS tablets whole with water. Do not split, crush, or chew tablets.

Missed Dose

If a dose is missed within 12 hours, take the dose. If a dose is missed by more than 12 hours, skip the missed dose and take the next scheduled dose.

Vomited Dose

If a dose is vomited, do not take an additional dose. Take the next dose at the regularly scheduled time.

The recommended dose reductions for adverse reactions are presented in Table 1.

Current HERNEXEOS Dose | First Reduction | Second Reduction

180 mg | 120 mg | 60 mg

120 mg | 60 mg | Permanently discontinue

Permanently discontinue HERNEXEOS in patients who are unable to tolerate 60 mg once daily.

The recommended dosage modifications for adverse reactions are presented in Table 2.

Adverse Reaction | Severity* | Dosage Modification

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal

*Based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Hepatotoxicity | Grade 3 or 4 ALT and/or AST without increased total bilirubin | Interrupt HERNEXEOS until recovered to ≤ Grade 1 or baseline.

Resume HERNEXEOS at reduced dose level.

Grade 3 total bilirubin | Interrupt HERNEXEOS until recovered to ≤ Grade 1 or baseline.

Resume HERNEXEOS at reduced dose level.

Grade 4 total bilirubin | Permanently discontinue HERNEXEOS.

ALT or AST ≥ 3× ULN with total bilirubin ≥ 2× ULN | Permanently discontinue HERNEXEOS.

Left Ventricular Dysfunction

| LVEF 40 to 50% and decrease from baseline of 10 to 19% | Interrupt HERNEXEOS until recovered to ≤ Grade 1 or within 10% from baseline.

If recovered to ≤ Grade 1 in ≤ 4 weeks, resume HERNEXEOS at the same dose level.

If not recovered to ≤ Grade 1 within 4 weeks, permanently discontinue HERNEXEOS.

LVEF 20 to 39% or ≥ 20% decrease from baseline | Interrupt HERNEXEOS until recovered to ≤ Grade 1 or within 10% from baseline.

If recovered to ≤ Grade 1 in ≤ 4 weeks, resume HERNEXEOS at the reduced dose level.

If not recovered to ≤ Grade 1 within 4 weeks, permanently discontinue HERNEXEOS.

Symptomatic Congestive Heart Failure | Permanently discontinue HERNEXEOS. …

How to take Zongertinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hepatotoxicity

Inform patients that HERNEXEOS can cause severe and life-threatening hepatotoxicity and that they will need to undergo lab tests to monitor liver enzymes during treatment . Advise patients to immediately contact their healthcare provider for signs and symptoms of hepatotoxicity.

Left Ventricular Dysfunction

Inform patients that HERNEXEOS can cause severe left ventricular dysfunction. Advise patients to immediately contact their healthcare provider for new or worsening cardiovascular symptoms .

Interstitial Lung Disease (ILD)/Pneumonitis

Inform patients that HERNEXEOS can cause severe or life-threatening ILD/pneumonitis. Advise patients to immediately contact their healthcare provider for new or worsening respiratory symptoms .

Diarrhea

Inform patients that HERNEXEOS can cause diarrhea. Advise patients to immediately contact their healthcare provider for new or worsening diarrhea .

Embryo-Fetal Toxicity

Advise females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy. …

Warnings & precautions

Do not take this medicine if: None.

HERNEXEOS can cause severe and life-threatening hepatotoxicity, including drug induced liver injury. In the pooled safety population , based on adverse reaction data, hepatotoxicity occurred in 27% of patients treated with HERNEXEOS. Grade 3 drug induced liver injury occurred in 1.4% and Grade 4 in 0.3% of patients treated with HERNEXEOS. Grade 3 hepatic failure occurred in 0.3% of patients treated with HERNEXEOS.

Based on laboratory data, 37% of patients treated with HERNEXEOS experienced increased alanine aminotransferase (ALT), including 4.9% Grade 3 and 1% Grade 4. Increased aspartate aminotransferase (AST) occurred in 31% of patients treated with HERNEXEOS, including 3.8% Grade 3 and 0.7% Grade 4. Increased bilirubin occurred in 20% of patients treated with HERNEXEOS, including 1% Grade 3 and 0.3% Grade 4.

HERNEXEOS was interrupted for an adverse reaction of hepatotoxicity in 8% of patients, the dose was reduced in 3.8% and permanently discontinued in 1%.

Monitor liver function tests including ALT, AST, and total bilirubin at baseline prior to administration of HERNEXEOS, every 2 weeks during the first 12 weeks, and then monthly thereafter as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Interrupt, reduce the dose, or permanently discontinue HERNEXEOS based on the severity of the adverse reaction .

HERNEXEOS can cause severe left ventricular dysfunction. Decreases in left ventricular ejection fraction (LVEF) have occurred with anti-HER2 therapies, including HERNEXEOS. Treatment with HERNEXEOS has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment.

In the pooled safety population , LVEF decrease occurred in 6% of patients treated with HERNEXEOS, including 1.7% Grade 3. …

Zongertinib side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Hepatotoxicity

Left Ventricular Dysfunction

Interstitial Lung Disease/Pneumonitis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The pooled safety population described in WARNINGS AND PRECAUTIONS reflects exposure to HERNEXEOS in 292 patients with unresectable or metastatic non-squamous NSCLC with HER2 (ERBB2) mutations who received HERNEXEOS as a single agent at 120 mg orally once daily until disease progression or unacceptable toxicity in Beamion LUNG-1 . Among 292 patients who received HERNEXEOS, 59% of patients were exposed for 6 months or longer and 28% were exposed for greater than one year. In this pooled safety population, the most common (≥ 20%) adverse reactions were diarrhea (54%), rash (28%), hepatotoxicity (27%), fatigue (25%), nausea (23%), musculoskeletal pain (21%), and upper respiratory tract infection (20%). The most common (≥ 2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes (10%), increased alanine aminotransferase (6%), increased aspartate aminotransferase (4.5%), increased gamma glutamyl transferase (2.8%), decreased potassium (2.4%), and decreased neutrophils (2.4%). …

Drug interactions

Avoid concomitant use of HERNEXEOS with strong CYP3A inducers. If concomitant use cannot be avoided, increase HERNEXEOS dose as recommended .

Zongertinib is a CYP3A substrate. Strong CYP3A inducers decrease zongertinib exposure , which may reduce effectiveness of HERNEXEOS.

BCRP Substrates

Avoid concomitant use of HERNEXEOS with certain BCRP substrates where minimal concentration changes may lead to serious adverse reactions. If coadministration cannot be avoided, monitor for increased adverse reactions and follow recommendations provided in the approved product labeling for the BCRP substrate. For other BCRP substrates, monitor for increased adverse reactions and adjust the dosages of those substrates as clinically appropriate.

Zongertinib is a BCRP inhibitor. HERNEXEOS increases exposure of BCRP substrates , which may increase the risk of adverse reactions related to these substrates.

About this medicine

HERNEXEOS tablets for oral administration contain zongertinib, a kinase inhibitor. The chemical name of zongertinib is 2-Propenamide, N-[1-[8-[[3-methyl-4-[(1-methyl-1H-benzimidazol-5-yl)oxy]phenyl] amino]pyrimido[5,4-d]pyrimidin-2-yl]-4-piperidinyl]-. Its molecular formula is C29H29N9O2 and the molecular weight is 535.6. The structural formula is:

Zongertinib is a yellow to dark yellow or orange solid. Zongertinib is slightly soluble at pH 1.2, and practically insoluble at pHs 3.6, 4.5, 5.4 and 6.8.

Each film-coated tablet of HERNEXEOS contains 60 mg of zongertinib and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. In addition, the film-coating contains the following inactive ingredients: ferric oxide (yellow), glycerol mono and dicaprylocaprate, polyvinyl alcohol, sodium lauryl sulfate, talc, and titanium dioxide.

How it works: Zongertinib is a kinase inhibitor of human epidermal growth factor receptor 2 (HER2). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d3fabf12-354e-4e5c-b5de-20fdb579b783. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate